Navigation Links
Lilly Grants $4.4 Million to the WHO for MDR-TB Program Expansion
Date:3/12/2008

INDIANAPOLIS and LONDON, March 12 /PRNewswire-FirstCall/ -- Today Eli Lilly and Company announced its four-year grant of $4,384,000 to the World Health Organization (WHO) for scaling up its global capacity to manage multi- drug resistant tuberculosis (MDR-TB) programs.

The grant covers four activities, starting with the technical assistance the WHO will provide to developing countries that the Global Fund to Fight AIDS, Tuberculosis and Malaria operations do not cover. The WHO will provide assistance to some 25 countries in their clinical management of MDR-TB, infection control, laboratory facilities and community outreach. Second, the WHO will conduct workshops for health care personnel so they can better design and manage TB programs, for laboratory technicians so they can test for first and second line drug susceptibility, and for administrative personnel to record and report on TB incidence in their countries. A third component is support for training global MDR-TB experts so they can expand training in developing countries, run workshops in infection control, and strengthen laboratories for proper diagnosis and treatment. Finally, the grant will support the field-testing and evaluation of a new information system to record and report on MDR-TB rates in two countries.

"This grant represents Lilly's continued commitment to support the WHO in its goal of treating 50 million TB patients and 1.6 million MDR-TB patients by 2015. It builds upon existing WHO and Lilly program successes in curbing the MDR-TB pandemic," says Alex Azar, senior vice president of corporate affairs and communications for Lilly. "With drug resistance at an all time high, the engagement in fighting MDR-TB comprehensively is more important now than ever."

Since 2003, approximately 30,000 patients have been enrolled on treatment in WHO Green Light Committee approved projects. Country officials and healthcare personnel have consistently identified the training of human
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Newly Labeled Therapies for Neuropathic Pain, Including Drugs From Pfizer and Eli Lilly, Will Drive Growth in the Chronic Pain Drug Market
2. Mental Health Parity Laudable, But House Legislation Would Put Medicaid Patients at Risk, Lilly Says
3. FDA Issues Not-Approvable Letter for Lillys Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
4. Lilly and Partners In Health, Brigham and Womens Hospital Team Up to Fight MDR-TB in Former Soviet Republics
5. Michael L. Eskew Elected to Lilly Board of Directors
6. Lilly Caps Successful Year with Strong Fourth-Quarter Results
7. Lilly Sets Date and Conference Call for Fourth Quarter and Full Year 2007 Financial Results Announcement
8. Lilly Announces Dividend Increase
9. Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy
10. International Federation-Lilly Agreement Will Allow Significant Increase in MDR-TB Programmes
11. JDRF and Lilly partner to fund research to identify beta cell biomarkers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2008)...s supporting the US Department of Defense and Fede...n Phoenix. Operation Golden Phoenix is a, four-d...gned to assist, federal, state and local agencies ...ios. Dataline is providing a vital, ad-hoc, secure...l use during the exercise., NORFOLK, Va., July 25...
(Date:7/25/2008)...Relationship Based on Significant Improvements in ... MDdatacor, Inc., a leader in health,care quality ...s, today,announced it has entered into a long-term...ort Wellmark,s Collaboration on Quality(SM) Incent...tion between Wellmark and,primary care clinicians ...
(Date:7/25/2008)...BURG, Ill., July 25 /PRNewswire/ -- Sagent Pharmac...eutical company, today announced that it,has launc...iarrhythmic,indicated for the treatment and prophy...tion and hemodynamically unstable ventricular,tach...r heart beat.,Sagent,s amiodarone HCl injection wi...
(Date:7/25/2008)...to benefit ALS Therapy Alliance to be presented at...t, WOONSOCKET, R.I., July 25 /PRNewswire/ -- CVS/...sed a record-breaking $4.4 million in just 21 days...for ALS research. This is,the seventh year of the ...ed more than $15 million for ALS research. This ye...
Breaking Medicine News(10 mins):Health News:Dataline Announces Participation in Operation Golden Phoenix 2Health News:Dataline Announces Participation in Operation Golden Phoenix 3Health News:MDdatacor Extends Contract with Wellmark, Inc. 2Health News:MDdatacor Extends Contract with Wellmark, Inc. 3Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 2Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 3Health News:CVS/pharmacy Raises Record-breaking $4.4 Million for ALS Research Through Annual ALS Fundraising Campaign 2
... in the British Medical Journal, researchers at Ox...e as 2 per cent in the consumption of common foods...er cent increase in coronary heart disease. Trans...ure and shelf life of food and is added to most fa...
...rams help to reduce sexual activities among young ...hout interfering in future condom use, according//...tion strategy.The study was conducted on 662 Afric...ity middle schools in Philadelphia and it was foun...
... prevention of discrimination against HIV/AIDS vic...efore the Cabinet for approval.// In the light of...th Minister Anbumani Ramadoss said, "it took a lit...nts to the draft and elaborate discussions with th...
...ay be more appropriate in men with low-risk prosta...surgery or radiation therapy, according to a resea...bor. The results of the study conducted by lead r...ciates have been published in the Journal of the N...
Other Medicine News:Health News:HIV Prevention through Abstinence-only Programs 2Health News:Legislation to Prevent Discrimination against HIV/AIDS Victims 2Health News:Watchful Waiting Effective for Low Risk Prostate Cancer 2
(Date:7/24/2008)...eeds Oncology Patient Accrual, DENVER, July 24 /P...ent,Organization (RMO), has contracted with five l...h and site management services for their,clinical ...ategy. The new,trials include the following diseas...Metastatic Breast Cancer, Metastatic Sarcoma, Chro...
(Date:7/23/2008)...in July print edition of Clinical ...uly 23 /- A Roche Diagnostics-sponsor...o-B-type natriuretic peptide,(NT-proBNP) confirms ...cation in predicting the risk of cardiovascular ad...steroidal anti-inflammatory drugs of,the COX inhib...
(Date:7/23/2008).../ -- InCode BioPharmaceutics, Inc.,an emerging bi...al test,results demonstrating the utility of their...e rare chronic blood disorder paroxysmal nocturnal...e presented at the XXII,International Complement W..., The only treatment currently available for PNH ...
(Date:7/22/2008)...-- Nonin Medical, a leading innovator,of physiolog...has entered,the clinical testing phase with its br...aturation. Today,s most common application for thi...egional blood oxygenation,in the brain -- cerebral...an ongoing clinical study at the,Duke University M...
Breaking Medicine Technology:Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials 2Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 2Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 3Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 4InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) 2Nonin Medical Inc. Announces Entry Into the Cerebral Oximeter Market 2Advanced Energy Consortium will develop micro and nanosensors to boost energy production 2605 1Advanced Energy Consortium will develop micro and nanosensors to boost energy production 2605 2Pelosi Democrats Host Health Care Forum This Morning 9587 1Pelosi Democrats Host Health Care Forum This Morning 9587 2Pelosi Democrats Host Health Care Forum This Morning 9587 3Pelosi Democrats Host Health Care Forum This Morning 9587 4Wisconsin Physicians Service Insurance Corporation Files Suit Against Aurora Health Care and HealthEOS 9583 1Wisconsin Physicians Service Insurance Corporation Files Suit Against Aurora Health Care and HealthEOS 9583 2The Widener University Elder Pennsylvanian Survey Finds Pennsylvanias Baby Boomers Anticipate Working Longer Retiring Later to Help Offset Looming He 9579 1The Widener University Elder Pennsylvanian Survey Finds Pennsylvanias Baby Boomers Anticipate Working Longer Retiring Later to Help Offset Looming He 9579 2The Widener University Elder Pennsylvanian Survey Finds Pennsylvanias Baby Boomers Anticipate Working Longer Retiring Later to Help Offset Looming He 9579 3The Widener University Elder Pennsylvanian Survey Finds Pennsylvanias Baby Boomers Anticipate Working Longer Retiring Later to Help Offset Looming He 9579 4
...stCall/ -- Kosan,Biosciences Incorporated presente...KOS-1584/R1645, an epothilone under,co-development...vity and tolerability in patients with solid tumor...ts (13 of 41,evaluable) including activity in pati...ostate, head and neck and other cancers. Common,to...
... IL, June 04, 2007,/PRNewswire-FirstCall/ - Cardio...ellas Pharma US, Inc. ("Astellas") today,announced...nical,study, called ACT 2. The trial evaluated the...n of vernakalant hydrochloride,("vernakalant (iv)"...al fibrillation or atrial flutter between 24 hours...
Other Medicine Technology:Kosan Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Epothilone KOS-1584 at ASCO 2Kosan Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Epothilone KOS-1584 at ASCO 3Kosan Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Epothilone KOS-1584 at ASCO 4Kosan Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Epothilone KOS-1584 at ASCO 5Cardiome And Astellas Announce Positive Results From ACT 2 Trial 2Cardiome And Astellas Announce Positive Results From ACT 2 Trial 3Cardiome And Astellas Announce Positive Results From ACT 2 Trial 4Cardiome And Astellas Announce Positive Results From ACT 2 Trial 5Cardiome And Astellas Announce Positive Results From ACT 2 Trial 6
...ical Professional Diagnostics is a leading provide...IFA and DFA test menu that includes kits for autoi...ll as miscellaneous conjugates and components. Our...t of substrates and kit sizes to choose from. Kit ...
...ical Professional Diagnostics is a leading provide...IFA and DFA test menu that includes kits for autoi...ll as miscellaneous conjugates and components. Our...t of substrates and kit sizes to choose from. Kit ...
...ical Professional Diagnostics is a leading provide...IFA and DFA test menu that includes kits for autoi...ll as miscellaneous conjugates and components. Our...t of substrates and kit sizes to choose from. Kit ...
...ical Professional Diagnostics is a leading provide...IFA and DFA test menu that includes kits for autoi...ll as miscellaneous conjugates and components. Our...t of substrates and kit sizes to choose from. Kit ...
Medicine Products: